Complex Arrhythmia Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing Anzhen Hospital
About this trial
This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).
Scheduled to undergo first-time catheter ablation for AF.
Procedure to be performed using a 3D mapping system.
Disqualifiers
Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).
AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).
Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure.
Severe active infection (e.g., septic shock, sepsis).
Trial design
Treatments tested in this trial
- AF ablation
- VT ablation
Treatment groups
4,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov